ReviewCells2021
Clinical Applications of Cell-Scaffold Constructs for Bone Regeneration Therapy.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Mesenchymal stem cells therapy for the treatment of non-union fractures: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2025Pooled it
- Effect of combination of osteoblasts and octacalcium phosphate collagen composite on bone regeneration in rat calvarial bone defect.Medical molecular morphology · 2026Article
- Nrf2-Keap1 Axis Modulation by Phytofabricated Metal Oxide Nanoparticles in Mesenchymal Stem Cell Lineage Bias.Journal of biochemical and molecular toxicology · 2026Review
- Biochemical and Physicomechanical Cues of Biomaterials Guide Osteogenic Differentiation of Mesenchymal Stem Cells.International journal of molecular sciences · 2026Review
- Directional bone matrix mineralization in the CAM assay is governed by vascular integration and matrix remodeling.bioRxiv : the preprint server for biology · 2026Article
- Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Advances in Functional Scaffolds for Bone and Joint Surgery.Journal of functional biomaterials · 2025Article
- Bone Regeneration in Rat Calvaria Using 3D-Printed Scaffolds with Graded Porosity and In Vitro Degradation.ACS omega · 2025Article
- The role of electrical stimulation in bone regeneration: mechanistic insights and therapeutic advances.Bioelectronic medicine · 2025Review
- BMP-2 mRNA-transfected BMSCs promote superior calvarial bone regeneration.Scientific reports · 2025Article
- Scaffold Application for Bone Regeneration with Stem Cells in Dentistry: Literature Review.Cells · 2024Review
- Review
- Towards Stem Cell Therapy for Critical-Sized Segmental Bone Defects: Current Trends and Challenges on the Path to Clinical Translation.Journal of functional biomaterials · 2024Review
- Navigating the Immunological Crossroads: Mesenchymal Stem/Stromal Cells as Architects of Inflammatory Harmony in Tissue-Engineered Constructs.Bioengineering (Basel, Switzerland) · 2024Review
- Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms.Journal of biological engineering · 2024Review
- Composite Remineralization of Bone-Collagen Matrices by Low-Temperature Ceramics and Serum Albumin: A New Approach to the Creation of Highly Effective Osteoplastic Materials.Journal of functional biomaterials · 2024Article
- Regenerative treatment of canine osteogenic lesions with Platelet-Rich Plasma and hydroxyapatite: a case report.Frontiers in veterinary science · 2024Article
- Revolutionizing bone defect healing: the power of mesenchymal stem cells as seeds.Frontiers in bioengineering and biotechnology · 2024Review
- Review
- The effect of green synthesis of TiOVeterinary medicine and science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone tissue engineering (BTE) is a process of combining live osteoblast progenitors with a biocompatible scaffold to produce a biological substitute that can integrate into host bone tissue and recover its function. Mesenchymal stem cells (MSCs) are the most researched post-natal stem cells because they have self-renewal properties and a multi-differentiation capacity that can give rise to various cell lineages, including osteoblasts. BTE technology utilizes a combination of MSCs and biodegradable scaffold material, which provides a suitable environment for functional bone recovery and has been developed as a therapeutic approach to bone regeneration. Although prior clinical trials of BTE approaches have shown promising results, the regeneration of large bone defects is still an unmet medical need in patients that have suffered a significant loss of bone function. In this present review, we discuss the osteogenic potential of MSCs in bone tissue engineering and propose the use of immature osteoblasts, which can differentiate into osteoblasts upon transplantation, as an alternative cell source for regeneration in large bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.